PhotoCure Basal Cell Carcinoma Phototherapy Has “Niche” Market Potential
Executive Summary
PhotoCure's methyl aminolevulinate could be approved as part of a "niche" basal cell carcinoma phototherapy regimen for patients who are intolerant to other treatments, an FDA advisory committee said in voting against a broader indication